

Samuel Frank

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3289056/publications.pdf>

Version: 2024-02-01

58
papers

2,159
citations

331670
21
h-index

223800
46
g-index

59
all docs

59
docs citations

59
times ranked

2381
citing authors

#	ARTICLE	IF	CITATIONS
1	Current Guidelines for Classifying and Diagnosing Cervical Dystonia: Empirical Evidence and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 183-190.	1.5	15
2	Dystonia and Tremor. <i>Neurology</i> , 2021, 96, e563-e574.	1.1	46
3	Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease. <i>JAMA Neurology</i> , 2021, 78, 312.	9.0	83
4	Meaning and purpose in Huntington's disease: a longitudinal study of its impact on quality of life. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1668-1679.	3.7	8
5	Predictive modeling of spread in adult-onset isolated dystonia: Key properties and effect of tremor inclusion. <i>European Journal of Neurology</i> , 2021, 28, 3999-4009.	3.3	2
6	F08...Huntington's disease burden of illness (HDBOI): study methodology, sample representativeness and fieldwork risk mitigation strategy during the COVID-19 pandemic. , 2021, , .		0
7	F10...Development of assessments for later stage huntington's disease: HD structured interview of function and HD clinical status questionnaire. , 2021, , .		0
8	F07...Demographic characteristics and health resource use of the european participants from the huntington's disease burden of illness study (HDBOI). , 2021, , .		0
9	Clinical and Imaging Progression in the <sc>PARS</sc> Cohort: <sc>Long-term</sc> Follow-up. <i>Movement Disorders</i> , 2020, 35, 1550-1557.	3.9	23
10	Motor phenotype classification in moderate to advanced PD in BioFIND study. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 178-183.	2.2	20
11	How different aspects of motor dysfunction influence day-to-day function in huntington's disease. <i>Movement Disorders</i> , 2019, 34, 1910-1914.	3.9	3
12	Transportation innovation to aid Parkinson disease trial recruitment. <i>Contemporary Clinical Trials Communications</i> , 2019, 16, 100449.	1.1	6
13	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019, 62, 201-209.	2.2	15
14	Deutetrabenazine in the treatment of Huntington's disease. <i>Neurodegenerative Disease Management</i> , 2019, 9, 31-37.	2.2	14
15	Utilization of Hospice Services in a Population of Patients With Huntington's Disease. <i>Journal of Pain and Symptom Management</i> , 2018, 55, 440-443.	1.2	15
16	P1...CEREBROSPINAL FLUID TAU, A β , AND STREM2 IN FORMER NATIONAL FOOTBALL LEAGUE PLAYERS: MODELING THE RELATIONSHIP BETWEEN REPETITIVE HEAD IMPACTS, MICROGLIAL ACTIVATION, AND NEURODEGENERATION. <i>Alzheimer's and Dementia</i> , 2018, 14, P275.	0.8	0
17	Cerebrospinal fluid tau, A β , and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. <i>Alzheimer's and Dementia</i> , 2018, 14, 1159-1170.	0.8	96
18	Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. <i>Movement Disorders</i> , 2018, 33, 282-288.	3.9	122

#	ARTICLE	IF	CITATIONS
19	Patient-reported outcome measures in Huntington disease: Quality of life in neurological disorders (Neuro-QoL) social functioning measures.. Psychological Assessment, 2018, 30, 450-458.	1.5	9
20	Patient-reported outcomes in Huntington's disease: Quality of life in neurological disorders (Neuro-QoL) and Huntington's disease health-related quality of life (HDQLIFE) physical function measures. Movement Disorders, 2017, 32, 1096-1102.	3.9	9
21	Reliability and Validity of the HD-PRO-Triad™, a Health-Related Quality of Life Measure Designed to Assess the Symptom Triad of Huntington's Disease. Journal of Huntington's Disease, 2017, 6, 201-215.	1.9	1
22	Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. JAMA Neurology, 2017, 74, 977.	9.0	209
23	Intermuscular coherence in amyotrophic lateral sclerosis: A preliminary assessment. Muscle and Nerve, 2017, 55, 862-868.	2.2	21
24	New symptomatic therapies for Huntington disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 144, 199-207.	1.8	4
25	Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease. JAMA - Journal of the American Medical Association, 2016, 316, 40.	7.4	327
26	The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Movement Disorders, 2016, 31, 924-932.	3.9	48
27	Study of plasma-derived miRNAs mimic differences in Huntington's disease brain. Movement Disorders, 2015, 30, 1961-1964.	3.9	36
28	Are therapeutic motivation and having one's own doctor as researcher sources of therapeutic misconception?. Journal of Medical Ethics, 2015, 41, 391-397.	1.8	22
29	Treatment of Huntington's Disease. Neurotherapeutics, 2014, 11, 153-160.	4.4	163
30	Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives. Tremor and Other Hyperkinetic Movements, 2014, 4, 224.	2.0	24
31	HD-PRO-TRIAD™ Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease. Tremor and Other Hyperkinetic Movements, 2014, 4, 223.	2.0	13
32	Epidemiology and Clinical Diagnosis of Parkinson Disease. PET Clinics, 2013, 8, 447-458.	3.0	6
33	Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset. Neurogenetics, 2013, 14, 173-179.	1.4	10
34	Botulinum Toxin for Painful Spasms From Focal Seizures. Neurologist, 2013, 19, 15-16.	0.7	3
35	Writing From the Wards. Neurologist, 2012, 18, 96-98.	0.7	2
36	Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset. Human Genetics, 2012, 131, 1833-1840.	3.8	26

#	ARTICLE	IF	CITATIONS
37	TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochemical and Biophysical Research Communications, 2012, 424, 404-408.	2.1	20
38	Sham surgery controls in Parkinson's disease clinical trials: Views of participants. Movement Disorders, 2012, 27, 1461-1465.	3.9	19
39	Common SNP-Based Haplotype Analysis of the 4p16.3 Huntington Disease Gene Region. American Journal of Human Genetics, 2012, 90, 434-444.	6.2	60
40	Comparison of enrollees and decliners of Parkinson disease sham surgery trials. Movement Disorders, 2012, 27, 506-511.	3.9	14
41	Managing chorea in Huntington's disease. Neurodegenerative Disease Management, 2011, 1, 295-306.	2.2	1
42	Use of Tetrabenazine in Huntington Disease Patients on Antidepressants or with Advanced Disease: Results from the TETRA-HD Study. PLOS Currents, 2011, 3, RRN1283.	1.4	14
43	Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatric Disease and Treatment, 2010, 6, 657.	2.2	83
44	Advances in the Pharmacological Management of Huntington's Disease. Drugs, 2010, 70, 561-571.	10.9	56
45	Financing graduate medical education. Nature Clinical Practice Neurology, 2009, 5, 58-59.	2.5	1
46	Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurology, 2009, 9, 62.	1.8	133
47	Trust in early phase research: therapeutic optimism and protective pessimism. Medicine, Health Care and Philosophy, 2008, 11, 393-401.	1.8	8
48	Ethics of sham surgery: Perspective of patients. Movement Disorders, 2008, 23, 63-68.	3.9	52
49	A Study of Chorea After Tetrabenazine Withdrawal in Patients With Huntington Disease. Clinical Neuropharmacology, 2008, 31, 127-133.	0.7	59
50	Long-term fetal cell transplant in Huntington disease: Stayin' alive. Neurology, 2007, 68, 2055-2056.	1.1	6
51	Teaching residents to be teachers. Nature Clinical Practice Neurology, 2007, 3, 236-237.	2.5	0
52	Trauma-induced spinal vascular event producing hemipseudoathetosis. Movement Disorders, 2005, 20, 1378-1380.	3.9	3
53	What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports. Neurology, 2005, 65, 1101-1103.	1.1	53
54	Science and Ethics of Sham Surgery. Archives of Neurology, 2005, 62, 1357.	4.5	87

#	ARTICLE	IF	CITATIONS
55	Mood fluctuations in Parkinson's disease: a pilot study comparing the effects of intravenous and oral levodopa administration. Neuropsychiatric Disease and Treatment, 2005, 1, 261-8.	2.2	4
56	The Challenges of Residents Teaching Neurology. Neurologist, 2004, 10, 216-220.	0.7	10
57	The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations. Cognitive and Behavioral Neurology, 2004, 17, 201-7.	0.9	66
58	Medical errors on an inpatient neurology service. Neurology, 2003, 61, 254-257.	1.1	9